Trade Abbvie - ABBV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.16 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 160.27 |
| Open | 160.36 |
| 1-Year Change | 9.27% |
| Day's Range | 160.35 - 161.34 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 9, 2024 | 160.27 | -0.19 | -0.12% | 160.46 | 161.22 | 159.95 |
| May 8, 2024 | 160.29 | -1.67 | -1.03% | 161.96 | 162.75 | 159.80 |
| May 7, 2024 | 162.43 | 0.38 | 0.23% | 162.05 | 163.85 | 161.77 |
| May 6, 2024 | 162.61 | -0.81 | -0.50% | 163.42 | 164.44 | 160.91 |
| May 3, 2024 | 163.71 | 3.13 | 1.95% | 160.58 | 164.17 | 160.52 |
| May 2, 2024 | 160.71 | -0.52 | -0.32% | 161.23 | 161.23 | 158.07 |
| May 1, 2024 | 161.47 | -0.22 | -0.14% | 161.69 | 163.64 | 160.97 |
| Apr 30, 2024 | 162.63 | 1.68 | 1.04% | 160.95 | 162.97 | 159.23 |
| Apr 29, 2024 | 161.38 | 2.06 | 1.29% | 159.32 | 161.48 | 158.48 |
| Apr 26, 2024 | 159.50 | -5.86 | -3.54% | 165.36 | 166.93 | 157.55 |
| Apr 25, 2024 | 167.16 | 1.16 | 0.70% | 166.00 | 168.88 | 165.48 |
| Apr 24, 2024 | 167.75 | -0.27 | -0.16% | 168.02 | 169.01 | 166.69 |
| Apr 23, 2024 | 169.40 | 1.77 | 1.06% | 167.63 | 170.30 | 167.63 |
| Apr 22, 2024 | 167.77 | 1.61 | 0.97% | 166.16 | 169.52 | 166.14 |
| Apr 19, 2024 | 166.31 | 1.73 | 1.05% | 164.58 | 166.54 | 163.00 |
| Apr 18, 2024 | 164.56 | 0.35 | 0.21% | 164.21 | 167.37 | 164.21 |
| Apr 17, 2024 | 164.10 | 1.03 | 0.63% | 163.07 | 164.64 | 163.04 |
| Apr 16, 2024 | 162.37 | 1.20 | 0.74% | 161.17 | 163.65 | 161.17 |
| Apr 15, 2024 | 161.60 | -2.41 | -1.47% | 164.01 | 164.57 | 161.19 |
| Apr 12, 2024 | 162.22 | -1.73 | -1.06% | 163.95 | 163.96 | 159.32 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AbbVie Company profile
AbbVie Inc. is a research-based pharmaceutical company, specialising in the discovery and development of biopharmaceuticals and small molecule drugs. With a team of around 29,000 scientists, researchers, manufacturing specialists and communications professionals across the globe, the company introduces new approaches to treating chronic conditions and life-threatening health issues. In 2019, AbbVie was ranked 96th on the Fortune 500 list of America’s biggest companies. More than 30 million patients in over 170 countries are treated by AbbVie’s medicines annually.
Headquartered in North Chicago, Illinois, AbbVie has 22 primary research and manufacturing facilities around the world. The company’s research centres are in the US, Germany and Japan; and its manufacturing sites are located in the USA, Puerto Rico, Ireland, Germany, Italy and Singapore.
The company produces medicines aimed at treating autoimmune diseases, cancers, viruses (including hepatitis C and HIV), neurological and metabolic disorders. According to the Wall Street Journal, in 2016, a specialty drug ibrutinib, retailed by the company, cost from $116,600 to $155,400 a year wholesale in the US. AbbVie estimates global sales of the drug at $5 billion in 2020.
The history of AbbVie started in 2013 when Abbott Laboratories split into two publicly traded companies. One, using the old company name, was to specialise in medical equipment and devices and nutritional products; the other, AbbVie, was to be a research-driven pharmaceutical manufacturer. From the start, AbbVie was interested in acquisitions: in 2014, it acquired ImmuVen for an undisclosed amount, and in 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers.
Presently, the AbbVie share price is listed on the New York Stock Exchange (NYSE). It is also a constituent of both the S&P 100 and 500 indices. In 2018, AbbVie reported its annual revenues of over $32.75 billion. During the same year, the ABBV stock price hit an all-time high of $123. As of July 2019, the company’s market capitalisation was set at around $106.13 billion.
Get the latest news on the Abbvie share price and stay on top of the ABBV share price chart with Capital.com.
| Industry: | Pharmaceuticals (NEC) |
1 N Waukegan Rd
NORTH CHICAGO
ILLINOIS 60064
US
News
Stock market crash: how far can the S&P 500 go?
After a remarkably strong first quarter, the US stock market pulled back in April for the first time since October last year.
11:46, 10 May 2024
Bank of England preview: possible rate cut in summer?
The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.
12:39, 8 May 2024
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com